> DOSE LOG / 03
Tesamorelin dosage, as studied in the trials
The regimens that appear in the published tesamorelin record — the dose, the route, the stability constraints, and the reported side effects — logged as study facts, never as a personal recommendation.
Before the details
This page describes what doses researchers gave, to whom, and how — it is not dosing guidance. The number that recurs across the tesamorelin dosage literature is 2 mg once a day, injected under the skin of the abdomen, the same regimen the FDA approved for the HIV use [1][5]. "Subcutaneous" just means a shallow injection into the fat layer, not into a vein. Because the molecule clears the blood within minutes but keeps the body's IGF-1 raised all day, the studies used a once-daily schedule [11]. Research-grade tesamorelin sold for lab use is not the approved product, so no human dosing instructions appear here.
Tesamorelin dosage in the literature
The extensively studied regimen is tesamorelin 2 mg subcutaneously once daily — the dose used in both pivotal Phase 3 trials and the FDA-approved regimen [1][2][5]. A lower 1 mg/day arm was studied in a cognition trial and as a comparison arm in a type-2-diabetes safety trial, but the 2 mg once-daily paradigm is the one carrying the bulk of the visceral-fat evidence [2].
The only route studied in clinical trials, and the only FDA-approved route, is subcutaneous abdominal injection [1]. A 2 mg/day regimen sustained the -18% VAT reduction across 52 weeks [2], and the population PK-PD model that links that subcutaneous exposure to the GH/IGF-1 response confirmed once-daily dosing is consistent with the episodic GH stimulation [11]. None of this is a directive to self-administer: it is the dose that was studied, in the population it was studied in. The framing throughout is "studied at 2 mg/day in HIV patients," not a recommendation.
Half-life, route, and stability constraints
Three pharmacological facts shape the studied regimen. First, plasma clearance is rapid — apparent clearance near 1,060 L/h, with a terminal half-life reported on the order of about 26–38 minutes in secondary sources [11]. Second, the molecule is stabilized against DPP-IV: the N-terminal trans-3-hexenoic acid modification blocks the cleavage that inactivates native GHRH within minutes, which is the chemical basis for any sustained activity at all [1]. Third, it is supplied as a lyophilized (freeze-dried) powder requiring reconstitution; the FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window [1].
The net pharmacological picture is a short-lived plasma agent that produces a sustained downstream IGF-1 signal — a trigger for the body's own GH pulse rather than a circulating hormone reservoir [11].
The populations the doses were studied in
A dose only means what its study population means, and tesamorelin's regimens were almost entirely studied in HIV-positive adults on antiretroviral therapy. The 2 mg/day dose carried the pivotal 26-week trial of 412 patients [1], the 52-week program [2], the JAMA hepatic-steatosis RCT of 50 adults [3], the pooled predictor analysis of 806 patients across two RCTs [10], and the 2026 five-RCT meta-analysis [13]. Non-HIV human exposure to the same dose is limited to a 13-man mechanistic study [4]; no large general-population fat-loss trial has been completed at any dose.
That distribution is why the literature describes 2 mg/day as "the studied regimen in HIV-associated lipodystrophy" rather than a general dose. The pooled analysis even identified who responded — baseline metabolic syndrome, triglycerides >1.7 mmol/L, and white race predicted reaching VAT below 140 cm² — underlining that the dose was characterized inside a specific clinical population, not the open market [10]. Research-grade tesamorelin supplied for laboratory use carries none of the purity, potency, or population context of the studied product, and it is prohibited in sport under the WADA Prohibited List (category S2).
Tesamorelin side effects reported in trials
Tesamorelin side effects in the published record center on the consequences of stimulating the GH axis. The FDA label warns about stimulating endogenous GH and raising serum IGF-1; injection-site reactions are reported in the GH-secretagogue class. Fluid-related effects (such as water retention) are part of the broader growth-hormone-class warning profile noted in the label.
Glucose effects were modest in the studied cohorts: in 13 healthy men neither fasting glucose nor insulin-stimulated glucose uptake changed significantly [4], and over 52 weeks in HIV patients the glucose changes were not clinically significant [2]. The NIH LiverTox monograph assigns a likelihood score of E — unlikely cause of clinically apparent liver injury — with no reported attributable liver-injury cases [5]. Labeled contraindications include any preexisting active malignancy (IGF-1 is a growth factor), known hypersensitivity to tesamorelin or its excipients, and pregnancy. The durability caveat is logged separately: visceral fat reaccumulates on discontinuation [2][6].